Warning: The NCBI web site requires JavaScript to function. more...
Temozolomide and cisplatin in relapsed/refractory acute leukemia.
Seiter K, Katragadda S, Ponce D, Rasul M, Ahmed N.
J Hematol Oncol. 2009 May 22;2:21.
Related citations
Phase I study of temozolomide in relapsed/refractory acute leukemia.
Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed T.
J Clin Oncol. 2002 Aug 1;20(15):3249-53.
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
Horton TM, Thompson PA, Berg SL, Adamson PC, Ingle AM, Dolan ME, Delaney SM, Hedge M, Weiss HL, Wu MF, Blaney SM; Children's Oncology Group Study.
J Clin Oncol. 2007 Nov 1;25(31):4922-8.
Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.
Geoerger B, Vassal G, Doz F, O'Quigley J, Wartelle M, Watson AJ, Raquin MA, Frappaz D, Chastagner P, Gentet JC, Rubie H, Couanet D, Geoffray A, Djafari L, Margison GP, Pein F.
Br J Cancer. 2005 Sep 5;93(5):529-37.
A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.
Zustovich F, Lombardi G, Della Puppa A, Rotilio A, Scienza R, Pastorelli D.
Anticancer Res. 2009 Oct;29(10):4275-9.
Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Steinherz PG, Shukla N, Kobos R, Steinherz L.
Pediatr Blood Cancer. 2010 May;54(5):687-93.
IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S, Paydas S, Disel U, Sahin B.
Am J Ther. 2006 Sep-Oct;13(5):389-93.
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
Cooper BW, Veal GJ, Radivoyevitch T, Tilby MJ, Meyerson HJ, Lazarus HM, Koc ON, Creger RJ, Pearson G, Nowell GM, Gosky D, Ingalls ST, Hoppel CL, Gerson SL.
Clin Cancer Res. 2004 Oct 15;10(20):6830-9.
Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ, Kim DH, Sohn SK, Kim JG, Baek JH, Jeon SB, Moon JH, Ahn BM, Lee KB.
Jpn J Clin Oncol. 2005 Oct;35(10):612-6. Epub 2005 Sep 19.
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS.
Clin Cancer Res. 2005 Dec 1;11(23):8403-12.
Treatment of refractory or relapsed adult acute leukemia by using mitoxantrone-containing regimens.
Lin MT, Chen YC, Liu TW, Tien HF, Liu MC, Wang CH, Shen MC, Liu CH.
Taiwan Yi Xue Hui Za Zhi. 1989 Nov-Dec;88(11-12):1116-22.
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Hashmi KU, Khan B, Ahmed P, Raza S, Hussain I, Mahmood A, Iqbal H, Malik HS, Anwar M.
J Pak Med Assoc. 2005 Jun;55(6):234-8.
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL.
J Clin Oncol. 2008 Nov 10;26(32):5192-7. Epub 2008 Oct 14.
A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll WL.
Leukemia. 2009 Dec;23(12):2259-64. Epub 2009 Sep 10.
Treatment of relapsed or refractory acute leukemia in childhood with bisantrene combined with high dose aracytine.
Leblanc T, Deméocq F, Leverger G, Baruchel A, Lemerle S, Vannier JP, Nelken B, Guillot T, Schaison G.
Med Pediatr Oncol. 1994;22(2):119-24.
Cisplatin increases sensitivity of human leukemic blasts to triazene compounds.
Piccioni D, D'Atri S, Papa G, Caravita T, Franchi A, Bonmassar E, Graziani G.
J Chemother. 1995 Jun;7(3):224-9.
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, Diab SG, Hammond LA, Johnson T, Villalona-Calero M, Fraass U, Statkevich P, Von Hoff DD, Eckhardt SG.
Clin Cancer Res. 1999 Jul;5(7):1629-37.
[Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY, Yang LJ, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Sun J, Liu QF.
Ai Zheng. 2003 Dec;22(12):1330-3. Chinese.
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P.
J Clin Oncol. 1993 Oct;11(10):2002-9.
Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
Kantarjian HM, Beran M, O'Brien S, Robertson L, Siddik Z, Yoshida M, Yang LY, Rios MB, Keating MJ, Meyer M, et al.
Leukemia. 1996 Mar;10(3):396-401.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on